Non-small-cell lung cancer.

Autor: Hendriks LEL; Department of Pulmonary Diseases, GROW-School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., Remon J; Department of Cancer Medicine, Gustave Roussy, Villejuif, France., Faivre-Finn C; Radiotherapy Related Research, University of Manchester and The Christie NHS Foundation, Manchester, UK., Garassino MC; Thoracic Oncology Program, Section of Hematology Oncology, Department of Medicine, the University of Chicago, Chicago, IL, USA., Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA., Kerr KM; Department of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, Aberdeen, UK., Tan DSW; National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, Singapore., Veronesi G; Department of Thoracic Surgery, San Raffaele Scientific Institute, Milan, Italy., Reck M; Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany. m.reck@lungenclinic.de.
Jazyk: angličtina
Zdroj: Nature reviews. Disease primers [Nat Rev Dis Primers] 2024 Sep 26; Vol. 10 (1), pp. 71. Date of Electronic Publication: 2024 Sep 26.
DOI: 10.1038/s41572-024-00551-9
Abstrakt: Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and radiotherapeutic techniques and a deeper biological understanding of NSCLC that has led to innovative systemic treatment options have improved the prognosis of patients with NSCLC. In non-metastatic NSCLC, the combination of various perioperative strategies and adjuvant immunotherapy in locally advanced disease seem to enhance cure rates. In metastatic NSCLC, the implementation of novel drugs might prolong disease control together with preserving quality of life. The further development of predictive clinical and genetic markers will be essential for the next steps in individualized treatment concepts.
(© 2024. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: